SCHEMBL19010259

SCHEMBL19010259

CC(=O)c1nnc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2)cc1NCC1CCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 8/20 0.51
CDK4 P11802 1/20 0.44
CCND1 P24385 1/20 0.44
CCND2 P30279 1/20 0.44
CCND3 P30281 1/20 0.44
BPTF Q12830 1/20 0.44
MAPT P10636 6/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GFER P55789 5/20 0.43
GAA P10253 4/20 0.43
ALOX15 P16050 4/20 0.43
ALOX12 P18054 4/20 0.43
MAPK1 P28482 2/20 0.43
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17021305 0.93 SYK (0.56) SYKCDK4CCND1CCND2CCND3
SCHEMBL19010284 0.89 CDK4 (0.44) SYKCDK4CCND1CCND2CCND3
SCHEMBL19010271 0.85 SYK (0.52) SYKCDK4CCND1CCND2CCND3
SCHEMBL17021404 0.85 SYK (0.53) SYK
SCHEMBL19010245 0.85 MAPT (0.46) SYKBPTFMAPTMEN1KMT2A
SCHEMBL19010248 0.85 SYK (0.51) SYKCDK4CCND1CCND2CCND3
SCHEMBL19010272 0.83 SYK (0.50) SYKCDK4CCND1CCND2CCND3
SCHEMBL19010243 0.83 MAPT (0.64) SYKMAPTMEN1KMT2AGFER
SCHEMBL19010260 0.81 MAPT (0.54) SYKBPTFMAPTMEN1KMT2A
SCHEMBL19010258 0.81 GFER (0.50) SYKBPTFMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834548-B2 Pyridazine compounds as JAK inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS ALEXION PHARMACEUTICALS, INC. 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS JAK1, JAK2, JAK3 SYK 248/4885CDK4 163/4885CCND1 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.